Streptococcus pneumoniae

Thorax

Volumn 54, Issue 10, 1999, Pages 929-937

  Catterall, J R ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOKINE;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; DISEASE COURSE; HUMAN; NASOPHARYNX; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SPLEEN; STREPTOCOCCUS PNEUMONIAE;

EID: 0032883059     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.10.929     Document Type: Review

References (128)

1. Austrian R. Pneumococcus: the first one hundred years. Rev Infect Dis 1981;3:183-189.
2. Macfarlane J, Finch R, Ward M, et al. Hospital study of adult community-acquired pneumonia. Lancet 1982;i: 255-8.
3. British Thoracic Research Committee. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. QJ Med 1987;62:195-220.
4. Fang DG, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 1990;69:307-16.
5. Austrian R, Gold J. Pneumococcal bacteraemia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964;120:771-83.
6. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis 1981;3: S1-17.
7. Aszkenasy OM, Gearge RC, Begg NT. Pneumococcal bacteraemia and meningitis in England and Wales 1982-1992. Commun Dis Rep 1994;5:R45-50.
8. Giesecke J, Fredlund H. Increase in pneumococcal bacteraemia in Sweden. Lancet 1997;349:699-70.
9. Editorial. Acute respiratory infections in under-fives: 15 million deaths a year. Lancet 1985;ii: 699-701.
10. Janoff EN, Breiman RF, Dalcy CL, et al. Pneumococcal disease during HIV infection. Ann Intern Med 1992;117:314-24.
11. Appelbaum PC. Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae. Pediatr Infect Dis J 1996;15:932-9.
12. Pallarés R, Linares J, Vadillo M, et al. Resistance to pencillin and cephalosporins and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-80.
13. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333:481-6.
14. Johnson AP, Speller DCE, George RC, et al. Prevalence of antibiotic resistance and serotypes in pneumococci in England and Wales: results of observational surveys in 1990 and 1995. BMJ 1996;312:1454-6.
15. Woodhead MA. Antibiotic resistant organisms in respiratory disease. London. Lung and Information Agency, 1998. Fact sheet 98/1.
16. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
17. Perry FE, Catterall JR. The pneumococcus: host-organism interactions and their implications for immunotherapy and immunoprophylaxis. Thorax 1994;49:946-50.
18. George RC. The epidemiology of pneumococcal disease. In: Mayon-White RT, ed. The clinical impact of pneumococcal disease and strategies for its prevention. London: Royal Society of Medicine, 1995:1-7.
19. Dorca J, Manresa F. Community-acquired pneumonia: initial management and empiral treatment. In: Torres A, Woodhead M, eds. Pneumonia. Eur Respir Monogr 1997;3:36-55.
20. Wong CA, Macfarlane JT. Prevention of community-acquired pneumococcal and influenza infection in adults: a re-evaluation of vaccination. In Torres A, Woodhead M, eds. Pneumonia. Eur Respir Monogr 1997;3:56-81.
21. Avery OT, Dubos R. The protective action of a specific enzyme against type 3 pneumococus infection in mice. J Exp Med 1931;54:73-89.
22. Kelly T, Dillard PJ, Yother J. Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae. Infect Immun 1994;62:1813-9.
23. Tuomanen E, Rich R, Zak O. Induction of pulmonary inflammation by components of the pneumococcal cell surface. Am Rev Respir Dis 1987;135:869-74.
24. Henrichssen J. Six newly recognised types of Streptococcus pneumoniae. J Clin Microbiol 1995;33:2759-62.
25. Kalin M. Pneumococcal serotypes and their clinical relevance. Thorax 1998;53:159-62.
26. Knecht JC, Schiffman GR, Austrian R. Some biological properties of pneumococcus type 37 and the chemistry of its capsular polysaccharide. J Exp Med 1970;132:475-87.
27. Dillard JP, Vandersca MW, Yother J. Characterisation of the cassette containing genes for type 3 capsular polysaccharide biosynthesis in Streptococcus pneumoniae. J Exp Med 1995;181:973-83.
28. Garcia E, Arrecubieta C, Monars R, et al. A functional analysis of the Streptococcus pneumoniae genes involved in the synthesis of type 1 and type 3 capsular polysaccharides. Microb Drug Resist 1997;3:73-88.
29. Sniadack DH, Schwartz B, Lipman H, et al. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serological distribution of sterile site pneumococcal isolates from children-implications for vaccine strategies. Pediatr Infect Dis J 1995;14:503-10.
30. Robbins JB, Austrian R, Lee C, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983;148:1136-59.
31. Winkelstein JA, Tomasz A. Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid. J Immunol 1978;120:174-8.
32. Geelen S, Bhattacharyya, Tuomanen E. The cell wall mediates pneumococcal attachment to and cytopathology in human endothelial cells. Infect Immun 1993;61:1538-43.
33. Heumann D, Barras C, Severin C, et al. Gram-positive cell walls stimulate synthesis of tumor necrosis factor and interleukin-G by human monocytes. Infect Immun 1994;62:2715-21.
34. Tomasz A. Choline in the cell wall of a bacterium: novel type of polymer-linked choline in Pneumococcus. Science 1967;157:694-7.
35. Alonso de Velasco E, Verheul AFM, Verhoef J, et al. Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev 1995;59:591-603.
36. Paton JC, Andrew PW, Boulnois GJ, et al Molecular analysis of the pathogenicity of Streptococcus pneumoniae: the role of pneumococcal proteins. Annu Rev Microbiol 1993;47:89-115.
37. Paton JC, Berry AM, Lock RA. Molecular analysis of putative pneumococcal virulence proteins. Microbial Drug Resist 1997;3:1-10.
38. Watson DA, Musher DM, Verhoef J. Pneumococcal virulence factors and host immune responses to them. Eur J Clin Microbiol Infect Dis 1995;14:479-90.
39. Briles DE, Tart RC, Wu HY, et al. Systemic and mucosal protective immunity to pneumococcal surface protein A. Ann NY Acad Sci 1996;797:118-26.
40. Kelly R, Greiff D. Toxicity of pneumococcal neuraminidase. Infect Immun 1970;2:115-7.
41. Scanlon KL, Diven WF, Glew RH. Purification and properties of Streptococcus pneumoniae neuraminidase. Enzyme 1989;41:143-50.
42. Humphrey JH. Hyaluronidase production by pneumococci. J Pathol Bacteriol 1948;55:273-5.
43. Verad M, Schutzbank T, Janoff A. Inhibitors of human neutrophil elastase in extracts of Streptococcus pneumoniae. Am Rev Respir Dis 1984;130:1118-24.
44. Killian M, Mestecky J, Schrohenloher RE. Pathogenic species of the genus Haemophilus and Streptococcus pneumoniae produce immunoglobulin A1 protease. Infect Immun 1979;26:143-9.
45. Courtney HS. Degradation of connective tissue proteins by serine proteases from Streptococcus pneumoniae. Biochem Biophys Res Commun 1991;175:1023-8.
46. Perry FE, Elson CJ, Greenham LW, et al. Interference with the oxidative response of neutrophils by Streptococcus pneumoniae. Thorax 1993;48:364-9.
47. Perry FE, Elson CJ, Mitchell TJ, et al. Characterisation of an oxidative response inhibitor produced by Streptococcus pneumonia. Thorax 1994;49:676-83.
48. Cundell DR, Pearce BJ, Sandros J, et al. Peptide permeases from Streptococcus pneumoniae affect adherence to eucaryotic cells. Infect Immun 1995;63:2493-8.
49. Berry AM, Paton JC. Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Infect Immun 1996;64:5255-62.
50. Spellerberg B, Cundell DR, Sandros J, et al. Pyruavate oxidase as a determinant of virulence in Streptococcus pneumonia. Mol Microbiol 1996;19:803-13.
51. Wizemann TM, Moskovitz J, Pearce BJ, et al. Peptide methionine sulphazide reductase contributes to the maintenance of adhesins in three major pathogens. Proc Natl Acad Sci 1996;93:7985-90.
52. Dintilhac A, Alloing G, Granadel C, et al. Competence and virulence of Streptococcus pneumoniae: Adc and PsaA mutants exhibit a requirement for Zn and Mn resulting from inactivation of putative ABC metal permeases. Mol Microbiol 1997;25:727-39.
53. Feldman C, Munro NC, Jeffery PK, et al. Pneumolysin induces the salient histological features of pneumococcal infection in the rat lung in vivo. Am J Respir Cell Mol Biol 1991;5:416-23.
54. Rayner CFJ, Jackson AD, Rutman A, et al. Interactions of pneumolysin-sufficient and -deficient isogenic variants of Streptococcus pneumoniae with human respiratory mucosa. Infect Immun 1995;63:442-7.
55. 55 Benton KA, Everson MP, Briles DE. A pneumolysin-negative mutant of Streptococcus pneumoniae causes chronic bacteraemia rather than acute sepsis in mice. Infect Immun 1995;63:448-55
56. Berry AM, Alexander JE, Mitchell TJ, et al. Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae. Infect Immun 1995;63:1969-74.
57. Rubins JB, Charboneau D, Paton JC, et al. Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J Clin Invest 1995;95:142-50.
58. Rubins JB, Charboneau D, Faching C, et al. Distinct roles for pneumolysin's cytotoxic and complement activities in the pathogenesis of pneumococcal pneumonia. Am J Respir Crit Care Med 1996;153:1339-46.
59. Canvin JR, Marvin AP, Sivakumaran M, et al. The role of pneumolysin and autolysin in the pathology of pneumonia and septicaemia in mice infected with a type 2 pneumococcus. J Infect Dis 1995;172:119-23.
60. Hakansson A, Carlstedt I, Davies J, et al. Aspects on the interaction of Streptococcus pneumoniae and Haemophilus influenzae with human respiratory tract mucosa. Am J Respir Crit Care Med 1996;154: S187-9.
61. Feldman C, Read R, Rutman A, et al. The interaction of Streptococcus pneumoniae with intact human respiratory mucosa in vitro. Eur Respir J 1992;5:576-85.
62. Andersson B, Eden CS. Mechanisms of pneumococcal attachment. Monogr Allergy 1988;24:44-5.
63. Gray BM, Dillon HC. Natural history of pneumococcal infections. Pediatr Infect Dis J 1989;8: S23-5.
64. Riley ID, Douglas RM. An epidemiological approach to pneumococcal disease. Rev Infect Dis 1981;3:233-45.
65. Gillespie SH. Aspects of pneumococcal infection including bacterial virulence, host response and vaccination. J Med Microbiol 1989;28:237-48.
66. Pons J L, Mandement M N, Martin E, et al. Clonal and temporal patterns of nasopharyngeal penicillin-susceptible and penicillin resistant Streptococcus pneumoniae strains in children attending a day care center. J Clin Microbiol 1996;34:3218-22.
67. Tuomanen EI, Austrian R, Masure RH. Pathogenesis of pneumococcal infection. N Engl J Med 1995;332:1280-4.
68. Musher DM, Groover JE, Reichler MR, et al. Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization. Clin Infect Dis 1997;24:441-6.
69. Weiser J N, Austrian R, Sreenivasan P K, et al. Phase variation in pneumococcal opacity: relationship between colononial morphology and nasopharyngeal colonization. Infect Immun 1994;62:2582-9.
70. Cundell D, Weiser JN, Shen J, et al. Relationship between colonial morphology and adherence of Streptococcus pneumoniae. Infect Immun 1995;63:757-61.
71. Rake G. Pathogenesis of pneumococcus infections in mice. J Exp Med 1935;63:191-209.
72. Wilson R, Dowling RB, Jackson AD. The biology of bacterial colonization and invasion of the respiratory mucosa. Eur Respir J 1996;9:1523-30.
73. Adamou JE, Wizemann TM, Barren P, et al. Adherence of Streptococcus pneumoniae to human bronchial epithelial cells (BEAS-2B). Infect Immun 1998;66:820-2.
74. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;146:1067-83.
75. Cundell DR, Tuomanen EI. Receptor specificity of adherence of Streptococcus pneumoniae to human type II pneumocytes and vascular endothelial cells in vitro. Microbial Pathogenesis 1994;17:361-74.
76. Sundberg-Kovamees M, Holme T, Sjogren A. Interaction of the C-polysaccharide of Streptococcus pneumoniae with the receptor asialo-GM1. Microbial Pathogenesis 1996;21:223-34.
77. Masure HR, Campbell EA, Cundell DR, et al. A new genetic strategy for the analysis of virulence in Streptococcus pneumoniae. In: Ferretti JJ, Gilmore MS, Klaenhammer TR, Brown F, eds. Genetics of streptococci, enterococci and lactococci. Dev Biol Stand. Vol 85. Basel: Karger, 1995:251-60.
78. Cundell DR, Gerrard NP, Gerrard C, et al. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 1995;377:435-8.
79. Doerschuk CM, Markos J, Koxson HO, et al. Quantitation of neutrophil migration in acute bacterial pneumonia in rabbits. J Appl Physiol 1994;77:2593-9.
80. Rich AR, MCKec CM. The pathogenicity of a virulent pneumococci for animals deprived of leukocytes. Bull J Hopkins Hosp 1939;64:434-46
81. Jonsson S, Musher DM, Chapman A, et al. Phagocytosis and killing of common bacterial pathogens of the lung by human alveolar macrophages. J Infect Dis 1985;152:4-13.
82. Toews GB, Vial WC. The role of C5 in polymorphonuclear leukocyte recruitment in response to Streptococcus pneumoniae. Am Rev Respir Dis 1984;129:82-6.
83. Boutten A, Dehoux MS, Seta N, et al. Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1996;153:336-42.
84. Hopkins H, Stull T, von Essen SG, et al. Neutrophil chemotactic factors in bacterial pneumonia. Chest 1989;95:1021-7.
85. Mizgerd JP, Meek BB, Kutkoski GJ, et al. Selectins and neutrophil traffic: margination and Streptococcus pneumoniae-induced emigration in murine lungs. J Exp Med 1996;184:639-45.
86. Doyle NA, Bhagwan SD, Meek BB, et al. Neutrophil margination, sequestration, and emigration in the lungs of L-selectin-deficient mice. J Clin Invest 1997;99:526-33.
87. Doerschuk CM, Winn RK, Coxson HO, et al. CD18-dependent and -independent mechanisms of neutrophil emigration in the pulmonary and systemic microcirculation of rabbits. J Immunol 1990;144:2327-33.
88. Cabellos C, Macintyre DE, Forrest M, et al. Differing roles for platelet-activating factor during inflammation of the lung and sub-arachnoid space. The special case of Streptococcus pneumoniae. J Clin Invest 1992;90:612-8.
89. Glynn P, Coakley R, O'Neill S. Soluble and surface adhesion molecules in community acquired pneumonia. Thorax 1997;52(Suppl 6): A13.
90. Lawrence E, van Eeden S, English D, et al. Polymorphonuclear leucocyte (PMN) migration in streptococcal pneumonia: comparison of older PMN with those recently released from the marrow. Am J Respir Cell Mol Biol 1996;14:217-24.
91. Terashima T, Wiggs B, English D, et al. Polymorphonuclear leucocyte transit times in bone marrow during streptococcal pneumonia. Am J Physiol 1996;271: L587-92.
92. Haslett C. Resolution of acute inflammation and the role of apoptosis in the tissue fate of granulocytes. Clin Sci 1992;83:639-48.
93. Haslett C. Granulocyte apoptosis and inflammaory disease. Br Med Bull 1997;53:669-83.
94. Dchoux MS, Boutten A, Ostinelli J, et al. Compartmentalised cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994;150:710-6.
95. Catterall JR, Sheffield EA. The lung and the immune system. In: Isenberg DA, Spiro SG, eds. Autoimmune aspects of lung disease. Basel: Birkhauser Verlag, 1998: 1-21.
96. 111Indium-labelled neutrophil flux into the lungs of bleomycin-treated rabbits assessed noninvasively by external scintigraphy. Am Rev Respir Dis 1989;140:756-63.
97. Jones HA, Clark RJ, Rhodes CG, et al. In vivo measurement of neutrophil activity in experimental lung inflammation. Am J Respir Crit Care Med 1994;149:1635-9.
98. Austrian R. Pneumococci. In: Davis BD, Dulbecco R, Isen HE, Ginsberg HS, eds. Microbiology, 3rd edn. Pennsylvania: Harper and Row, 1980: 592-606.
99. Musher DM, Chapman AJ, Goree A, et al. Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis 1986;154:245-6.
100. Musher DM, Luchi MJ, Watson DA, et al. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non type-specific cell wall polysaccharide. J Infect Dis 1990;161:728-35.
101. Brown EJ, Hosea SW, Frank MM. The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the blood stream. Rev Infect Dis 1983;5(Suppl 4):S797-805.
102. Cohn DA, Schiffman G. Immunoregulatory role of the spleen in the antibody responses to pneumococcal polysaccharide antigens. Infect Immun 1987;55:1375-80.
103. Herbert JC, O'Reilly M, Gamelli RL. Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg 1990;125:1075-8.
104. Nelson S, Mason CM, Kolls J, et al. Pathophysiology of pneumonia. Clin Chest Med 1995;16:1-12.
105. Malloy RG, Mannick JA, Rodrick ML. Cytokines, sepsis and immunomodulation. Br J Surg 1993;80:289-97.
106. Natonson C, Hoffman WD, Suffredini AF, et al. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994;120:771-83.
107. Donnelly SC, Strieter RM, Reid PT, et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann Intern Med 1996;125:191-6.
108. van Dissel JT, van Langevelde P, Westendorp RGJ, et al. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998;351:950-3.
109. van der Poll T, Marchant A, Keogh CV, et al. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996;174:994-1000.
110. van der Poll T, Keogh CV, Buurman WA, et al. Passive immunisation against tumor necrosis factor α impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med 1997;155:603-8.
111. Van der Poll T, Keogh CV, Guirao X, et al. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 1997;176:439-44.
112. Tasaki S, Warnock RA, Blain GC, et al. Interferon-γ gene expression in bacterial pneumonia in mice. Am J Respir Crit Care Med 1998;157(Suppl):A863.
113. Kawakami M, Tsutsumi H, Kumakawa T, et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 1990;76:1962-4.
114. Tazi A, Nioche S, Chastre J, et al. Spontaneous release of granulocyte colony-stimulating factor (G-CSF) by alveolar macrophages in the course of bacterial pneumonia and sarcoidosis: endotoxin-dependent and endotoxin-independent G-CSF release by cells recovered by broncho-alveolar lavage. Am J Respir Cell Mol Biol 1991;4:140-7.
115. Greenberger MJ, Strieter RM, Kunkel SL, et al. Neutralisation of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995;155:722-9.
116. Greenberger MJ, Strieter RM, Kunkel SL, et al. Neutralisation of macrophage inflammatory protein-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia. J Infect Dis 1996;173:159-65.
117. Greenberger MJ, Kunkel SL, Strieter RM., et al IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 1996;157:3006-12.
118. Moussa K, Michie HJ, Cree IA, et al. Phagocyte function and cytokine production in community acquired pneumonia. Thorax 1994;49:107-11.
119. Marik P, Kraus P, Bribante J, et al. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. Chest 1993;104:389-92.
120. Puren AJ, Feldman C, Savage N, et al. Patterns of cytokine expression in community-acquired pneumonia. Chest 1995;107:1342-9.
121. Glynn P, Coakley R, O'Neill S. Systemic IL-6 and IL-10 levels in community acquired pneumonia. Thorax 1997;52(Suppl 6):A13.
122. Chollet-Martin S, Montravers P, Gibert CG, et al. High levels of interlukin-8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome. Infect Immun 1993;61:4553-9.
123. Chollet-Martin S, Montravers P, Gibert CG, et al. Sub-population of hyperresponsive polymorphonuclear neutrophils in patients with adult respiratory distress syndrome. Am Rev Respir Dis 1992;146:990-6.
124. Cannon JG, Nerad JL, Poutsiaka DD, et al. Measuring circulating cytokines. J Appl Physiol 1993;75:1892-7.
125. Dinarello CA, Cannon JG. Cytokine measurements in septic shock. Ann Intern Med 1993;119:853-4.
126. Chollet-Martin S, Rouset F, Chastre J, et al. Cytokines in adult respiratory distress syndrome. Lancet 1994;344:1440.
127. Westendorp RGF, Langermans JAM, Huizinga TWJ, et al. Genetic influence on cytokine production and fatal menigococcal disease. Lancet 1997;349:170-3.
128. Vincent J-L. Search for effective immunomodulating strategies against sepsis. Lancet 1998;351:922-3.